The Swiss pharma company has reached a “tentative agreement” to settle a class-action lawsuit related to the launch of generic versions of its hypertension drug. The deal has yet to be approved by US judges.
This content was published on
2 minutes
Keystone-SDA/dos
Español
es
Novartis concluye acuerdo extrajudicial en Estados Unidos
The Basel-based multinational told the AWP news agency on Thursday it had agreed to pay $245 million (CHF227 million) to three groups of plaintiffs to fully settle the case.
The antitrust litigation stemmed from a 2011 patent agreement between Novartis and Par, a pharmaceutical subsidiary of US-based Endo International. The two companies were accused of illegally colluding to delay the launch of cheaper generic versions of Novartis’ Exforge, a treatment designed to lower blood pressure and reduce the risk of strokes.
The plaintiffs accused Par of agreeing not to launch an Exforge generic for two years after a patent expired, and Novartis of agreeing not to compete with Par by launching its own generic for 180 days after Par entered the market.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
In its statement, Novartis said the three groups which filed the lawsuit were direct purchasers, indirect purchasers and resellers. The out-of-court settlement, which has yet to be cleared by US judges, “will resolve all outstanding claims related to this matter for Novartis”, the company said.
According to court documents cited by Reuters, annual sales of Exforge in the US were over $400 million before the generic versions were marketed. Reuters also reports that the plaintiffs include major pharmacy chains such as CVS Health, Rite Aid and Walgreens Boots Alliance.
Popular Stories
More
Foreign affairs
What Trump’s return or a new Harris administration would mean for Switzerland
Should raw milk sales be banned or should consumers decide?
Swiss food regulations do not allow raw milk to be sold for direct consumption. However, a loophole allows 400 raw milk vending machines to do just that.
COP29: Swiss NGOs call for strong financial support
This content was published on
Ahead of COP29, Swiss NGOs call for wealthy nations to pay $1,000 billion a year to help other countries solve climate problems.
Real Swiss wages likely to rise in 2025, says UBS bank
This content was published on
Higher wages and falling inflation are likely to boost Swiss purchasing power, which will be dragged back by rising health premiums.
This content was published on
Switzerland has a new tectonic map at a scale of 1:500,000, containing updates to geometry, distribution and nomenclature of the tectonic units.
This content was published on
Swiss artist Daniel Spoerri, known for his artworks using leftover food with dirty cutlery and crockery, has passed away in Vienna at the age of 94.
Climate change tipped to alter Swiss avalanche patterns by 2100
This content was published on
Climate change is expected to result in fewer avalanches overall in Switzerland but to increase the danger of wet snow avalanches by 2100.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Competition authorities probe Novartis over suspected patent abuse
This content was published on
The Swiss competition commission (COMCO) has opened an investigation into suspected unlawful use of a patent by Novartis.
Novartis sets sights on high-value medicines and US market
This content was published on
Swiss pharma giant Novartis has unveiled an updated strategy focused on high-value medicines and boosting its position in the US market.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.